782 Survival in advanced-stage ovarian carcinoma with high VEGF-A expression after addition of bevacizumab. Results from the German ICON7 patient cohort

S Kommoss; F Heitz; L Serna-Higuita; TW Park-Simon; A Belau; L Hanker; KR Kimmig; N De Gregorio; B Schmalfeldt; K Baumann; W Schroeder; U Canzler; J Sehouli; A Burges; F Hilpert; P Martus; A Reuß; S Mahner; P Harter; J Pfisterer

doi:10.1136/ijgc-2021-ESGO.471

Article info

Ovarian cancer

782 Survival in advanced-stage ovarian carcinoma with high VEGF-A expression after addition of bevacizumab. Results from the German ICON7 patient cohort

Free

Authors

S Kommoss Tübingen University Hospital, Department of Women’s Health, Tübingen, Germany AGO Study Group, Wiesabden, Germany PubMed articles Google scholar articles
F Heitz AGO Study Group, Wiesabden, Germany Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Germany PubMed articles Google scholar articles
L Serna-Higuita Tuebingen University Hospital, Institut für Klinische Epidemiologie und angewandte Biometrie PubMed articles Google scholar articles
TW Park-Simon AGO Study Group, Wiesabden, Germany Hannover Medical School, Hannover, Germany PubMed articles Google scholar articles
A Belau AGO Study Group, Wiesabden, Germany Frauenarztpraxis Dr. Belau, Greifswald, Germany University Hospital Greifswald, Greifswald, Germany PubMed articles Google scholar articles
L Hanker AGO Study Group, Wiesabden, Germany University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany PubMed articles Google scholar articles
KR Kimmig AGO Study Group, Wiesabden, Germany University Hospital Essen, Essen, Germany PubMed articles Google scholar articles
N De Gregorio AGO Study Group, Wiesabden, Germany SLK-Kliniken Heilbronn, Klinikum am Gesundbrunnen, Gynecology and Obstetrics, Heilbronn, Germany PubMed articles Google scholar articles
B Schmalfeldt AGO Study Group, Wiesabden, Germany University Medical Center Hamburg-Eppendorf, Hamburg, Germany PubMed articles Google scholar articles
K Baumann AGO Study Group, Wiesabden, Germany Hospital Ludwigshafen, Gynecology and Obstetrics, Ludwigshafen, Germany PubMed articles Google scholar articles
W Schroeder AGO Study Group, Wiesabden, Germany Gynaekologicum Bremen, Bremen, Germany PubMed articles Google scholar articles
U Canzler AGO Study Group, Wiesabden, Germany University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany PubMed articles Google scholar articles
J Sehouli AGO Study Group, Wiesabden, Germany Charité – Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany PubMed articles Google scholar articles
A Burges AGO Study Group, Wiesabden, Germany University Hospital, LMU Munich, Department of Obstetrics and Gynecology, Munich, Germany PubMed articles Google scholar articles
F Hilpert AGO Study Group, Wiesabden, Germany Krankenhaus Jerusalem Hamburg, Hamburg, Germany PubMed articles Google scholar articles
P Martus Tuebingen University Hospital, Institut für Klinische Epidemiologie und angewandte Biometrie PubMed articles Google scholar articles
A Reuß Philipps-University Marburg, Coordinating Center for Clinical Trials, Marburg, Germany PubMed articles Google scholar articles
S Mahner AGO Study Group, Wiesabden, Germany University Hospital, LMU Munich, Department of Obstetrics and Gynecology, Munich, Germany PubMed articles Google scholar articles
P Harter AGO Study Group, Wiesabden, Germany Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Germany PubMed articles Google scholar articles
J Pfisterer AGO Study Group, Wiesabden, Germany Gynecologic Oncology Center, Kiel, Germany PubMed articles Google scholar articles

Citation

Kommoss S, Heitz F, Serna-Higuita L, et al

782 Survival in advanced-stage ovarian carcinoma with high VEGF-A expression after addition of bevacizumab. Results from the German ICON7 patient cohort

International Journal of Gynecologic Cancer 2021;31:A274.

Publication history

First published October 12, 2021.

Online issue publication

January 10, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password